Metastatic Dedifferentiated Liposarcoma research hub

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

This study looks at combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) for certain aggressive sarcomas. It compares this combination to chemotherapy alone, hoping to find a better way to stop the cancer from growing and spreading.